In conclusion, several well-conducted studies indicate that an association of chlorambucil or bendamustine and an anti-CD20 monoclonal antibody (i.e., rituximab, ofatumumab and obinutuzumab ...

New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic ...

Pentostatin + cyclophosphamide + rituximab. Phase I dose-finding study in patients with relapsed/refractory CLL (n = 57) [195] 86% ORR in treatment-naive CLL, 17% in relapsed/refractory CLL ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

Discover how exercise enhances cancer treatment effectiveness, boosts immunity, and improves patient outcomes with ...

BRUIN CLL-321 serves as the confirmatory trial to ... with pirtobrutinib or investigator's choice of idelalisib-rituximab or bendamustine-rituximab. Patients were mostly enrolled from Europe ...

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic ...

The results of two controlled trials, now published in the January 2010 issue of Arthritis and Rheumatism, suggest that treatment with the B-cell depleting agent, rituximab, lowers the response to ...

DLBCL: 1400mg/23400 Units over 5mins on Day 1 of Cycles 2–8 of CHOP chemotherapy for up to 7 cycles following a full dose of IV rituximab on Day 1 of Cycle 1. CLL: 1600mg/26800 Units over 7mins ...